InSilico Medicine Cayman TopCo (HKG:3696)
42.82
+2.98 (7.48%)
Jul 10, 2026, 4:08 PM HKT
InSilico Medicine Cayman TopCo Earnings Call Transcripts
Fiscal Year 2025
-
AI-driven drug discovery advanced with 28 developmental candidates, major deals including a $2.75B Eli Lilly partnership, and expanded AI platform capabilities. Revenue declined due to timing, but software segment grew and cash position remains strong. Multiple clinical and business milestones expected in 2026.